Biosimilars LatAm - Europe 2023 - Jackleckerman

pexels-antonio-lorenzana-bermejo-14423695

Biosimilars LatAm – Europe 2023

This forum serves as a space to showcase Latin America as a region rich with opportunities for the European market. The forum aims to establish a long-term partnership between the two continents by fostering mutual opportunities for business, networking, and market understanding.

Attendees will have the opportunity to explore a variety of key themes including market analysis, strategic alliances, and regulatory considerations, providing a valuable approach to connecting the two continents.

The event will feature presentations and participation from renowned industry experts, who will share their extensive knowledge, experience, and insights within the biotechnology field.

Program Scope:

The main objective is to research and assess the potential market and business opportunities within the European and Latin American regions, specifically Brazil, Mexico, Argentina, and Colombia.

The program aims to create and maintain productive partnerships and alliances while evaluating regulatory guidelines to guarantee compatibility, homogeneity, accessibility, and EU standards compliance.

Who will
you meet?

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

Biosimilars
Biobetters
Biotechnology
Biotherapeutics
Analytical science
Regulatory compliance
Quality Control
Clinical immunology
Scientific Affairs
Pharmacovigilance
Research
Regulatory
Business Development
Marketing

Speaker Board

Program at a Glance

Exploration of the Latin American Market and Comparison with the EU Market:

What does the Latin American market offer?

Reasoning behind the actual market landscape in Latin America.

Comparision of the two regions.

Comprehensive database of analysis, assessments, leading information, critical parameters, unprecedented occasions, strategic positions and potential.

Discovering the Latin American Alliances:

How to start a partnership in the region?

Partnerships for Productive Development, flow of information and relationships.

Benefits of mutual and fertile cooperation and enriching symbiosis.

Networking doors at local, regional, international level.

Regulatory Framework and Challenges:

How to get on and succeed on the road?

Implementation and pursuit of global broad and regulatory coverage.

European market achievements inspire Latin America.

Homogeneity, mutual cooperation, efficiency, flexibility, accessibility.

Connecting Europe with LatAm. Global Biosimilars Policy, Standards and Experience as Backbone

The biosimilar history started over 20 years ago in Europe, and has its foundations in thorough science. Positive experience has cumulated yet heterogeneity in progress among regions remains the number one challenge standing in the way of global adoption of biosimilar medicines.

Full programme in the PDF Agenda

Download Agenda

Merck

We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.

Visit Website

UDIBI

With 60+ dedicated scientists and support personal, UDIBI is a third-party laboratory authorized by the Mexican Regulatory Agency (COFEPRIS) to conduct analytical services for the pharmaceutical and medical devices industries. We also provide consulting services on antibody engineering and development of antibody-based therapeutics. With the support from government and private investment we have developed a portfolio of biotherapeutics that includes a product in the market and several therapeutic antibodies in diverse phases of discovery, optimization and preclinical development. In response to COVID-19 pandemic, UDIBI developed and commercializes the only 100% Mexican diagnostic kit to detect anti-SARS-CoV-2 antibodies with approval by COFEPRIS for commercialization in Mexico.

Visit Website

Sponsor the Forum

Photo Gallery from Previous Events

Open Gallery

104PHBIBR19-photo-gallery-2018-desktop-01

Testimonials

”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”

Alison Bascou, Sr. Regulatory Director at BD, France
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."

Jaime Uribe, CEO At PROBIOMED
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”

Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”

Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”

Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico